Tricyclic antidepressant amitriptyline alters sarcoplasmic reticulum calcium handling in ventricular myocytes.
Tricyclic antidepressants such as amitriptyline (AMT) have been reported to have adverse side effects on cardiac performance. AMT effects on Ca handling in ventricular myocytes, however, are not well understood. Therefore, we investigated AMT action on sarcoplasmic reticulum (SR) Ca release in ventricular myocytes, ryanodine receptor (RyR) activity, and Ca uptake by SR microsomes. In permeabilized myocytes, AMT transiently increased free luminal Ca concentration ([Ca]) followed by marked depletion. AMT (10 microM) caused a rapid and a transient increase of Ca spark frequency, followed by a significant suppression of spark activity. The latter was associated with a decrease of Ca spark amplitude and SR Ca load to 87 and 60%, respectively. AMT (10 microM) completely abolished propagation of spontaneous Ca waves. Higher concentrations of AMT (0.1-1 mM) evoked SR Ca release reminiscent of the effect of caffeine (20 mM) and caused almost complete depletion of SR Ca content. Studies on single calsequestrin-free RyR channels revealed that AMT increased the mean open time and open probability (Po) in a dose-dependent fashion (dissociation constant = 4.2 microM). High concentrations of AMT (> 25 microM) evoked frequent long openings with Po reaching very high levels (> 0.70). In studies with cardiac SR microsomes, AMT slowed the rate of ATP-dependent Ca uptake. We conclude that AMT affects SR Ca handling in ventricular myocytes by multiple mechanisms, including direct stimulation of RyRs and inhibition of SR Ca uptake. These effects could contribute to AMT cardiotoxicity.
Zima
Aleksey V
AV
Department of Molecular Biophysics and Physiology, Rush University Medical Center, 1750 W. Harrison Ave., Chicago, IL 60612, USA.
Qin
Jia
J
Fill
Michael
M
Blatter
Lothar A
LA
D000255:Adenosine Triphosphate / Q000378:metabolism; D000639:Amitriptyline / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology* / Q000633:toxicity; D002110:Caffeine / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects*; D002155:Calsequestrin / Q000378:metabolism; D002415:Cats; D004305:Dose-Response Relationship, Drug; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism; D008861:Microsomes; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D011817:Rabbits; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000187:drug effects* / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism
D000929:Antidepressive Agents, Tricyclic; D002155:Calsequestrin; D019837:Ryanodine Receptor Calcium Release Channel; D000639:Amitriptyline; D002110:Caffeine; D000255:Adenosine Triphosphate; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases
Eur J Clin Pharmacol. 1978 Nov 27;14(3):185-90
365538
Br J Pharmacol. 2000 Apr;129(7):1474-80
10742304
Circ Res. 2004 Mar 5;94(4):478-86
14699012
J Physiol. 1997 Aug 1;502 ( Pt 3):471-9
9279801
J Biol Chem. 1988 Jun 25;263(18):8958-64
3379055
Science. 1993 Oct 29;262(5134):740-4
8235594
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1167-71
3469659
Biophys J. 2005 May;88(5):3444-54
15731387
Circ Res. 2003 Jul 11;93(1):40-5
12791706
Biophys J. 2000 Jan;78(1):334-43
10620297
J Physiol. 2004 Mar 16;555(Pt 3):727-41
14724208
Am J Physiol. 1989 Feb;256(2 Pt 2):H328-33
2537030
Biophys J. 2001 Aug;81(2):785-98
11463625
Biophys J. 2004 Apr;86(4):2121-8
15041652
Circ Res. 2006 May 12;98(9):1151-8
16601229
Am J Physiol Cell Physiol. 2007 Sep;293(3):C1073-81
17376815
Br J Psychiatry. 1986 Jan;148:52-7
3513884
J Pharmacol Exp Ther. 2000 Mar;292(3):1015-23
10688618
Biophys J. 2008 Mar 1;94(5):1867-79
18024505
Circulation. 1995 Mar 1;91(5):1512-9
7867192
J Mol Cell Cardiol. 2007 Jan;42(1):34-50
17081562
Am Heart J. 1982 Mar;103(3):401-14
7039280
Am J Med. 1994 Dec 19;97(6A):24S-32S
7992823
Circ Res. 2002 Sep 6;91(5):414-20
12215490
Lancet. 2000 Mar 25;355(9209):1048-52
10744090
Circulation. 1995 Jan 1;91(1):201-14
7805204
Mol Pharmacol. 2005 Jan;67(1):97-104
15492117
Cardiovasc Res. 2008 Jan 15;77(2):302-14
18006486
J Biol Chem. 2004 Apr 23;279(17):18026-33
14871888
Circ Res. 2002 Oct 4;91(7):594-600
12364387
Arch Int Pharmacodyn Ther. 1979 Jul;240(1):116-36
507990
Biophys J. 1998 Dec;75(6):2801-10
9826602
J Biol Chem. 1983 Oct 10;258(19):11932-6
6619149
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11759-64
13130076
Br J Pharmacol. 1992 Jun;106(2):464-9
1382783
Am J Hum Genet. 2001 Dec;69(6):1378-84
11704930
Cardiovasc Res. 1998 Jun;38(3):589-604
9747428
Toxicol Rev. 2005;24(3):205-14
16390222
Circ Res. 2002 Oct 18;91(8):e21-6
12386154
J Biol Chem. 1985 Aug 15;260(17):9618-23
2991255